Immunome, Inc. (IMNM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Immunome, Inc. (IMNM) is down 10.7% since the beginning of the year. At $19 per share, IMNM is trading 30.6% below its 52-week high of $28. Investors who bought $1,000 worth of IMNM shares 5 years ago would now be looking at an investment worth $1,119.

Immunome, Inc. (IMNM) has returned -10.71% so far this year and 119.20% over the past 12 months.

Based on dividend-adjusted daily data since Oct 2, 2020, IMNM's average daily return is +0.20%, while the average monthly return is +4.98%. At this rate, an investment would double in approximately 1.2 years.

Historically, 43% of months were positive and 57% were negative. The best month was Feb 2021 with a return of +172.4%, while the worst month was Dec 2022 at -48.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, IMNM closed higher 47% of trading days. The best single day was Feb 18, 2021 with a return of +75.6%, while the worst single day was Mar 7, 2022 at -20.7%.

Immunome, Inc. has an annualized alpha of 30.44%, beta of 1.47, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since October 02, 2020.

• This stock participated in 203.62% of S&P 500 Index downside but only 203.34% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IMNM ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Immunome, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Immunome, Inc. was 94.89%, occurring on Dec 30, 2022. The portfolio has not yet recovered.

The current Immunome, Inc. drawdown is 55.64%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Immunome, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Immunome, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.